Jeil Pharm (002620) — Cash Flow-to-Debt Ratio
Jeil Pharm (002620) has a Cash Flow-to-Debt Ratio of 0.00x as of March 2026, meaning its operating cash flow of ₩447.08 Million could theoretically repay 0% of its total liabilities (₩403.14 Billion) in one year. Explore 002620 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jeil Pharm Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Jeil Pharm across 13 annual periods. Also explore balance sheet size of Jeil Pharm for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Jeil Pharm (2011–2025)
Year-by-year debt coverage analysis for Jeil Pharm. For market capitalisation and broader financial context, see market value of Jeil Pharm.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | ₩390.26 Million | ₩407.55 Billion | ▼ -90.4% |
| 2024 | 0.01x | ₩4.54 Billion | ₩453.04 Billion | ▲ +208.5% |
| 2023 | -0.01x | ₩-4.42 Billion | ₩477.81 Billion | ▲ +80.2% |
| 2022 | -0.05x | ₩-20.80 Billion | ₩445.88 Billion | ▼ -236.5% |
| 2021 | 0.03x | ₩13.40 Billion | ₩392.11 Billion | ▲ +156.0% |
| 2020 | -0.06x | ₩-23.67 Billion | ₩388.11 Billion | ▼ -187.9% |
| 2019 | 0.07x | ₩25.22 Billion | ₩363.44 Billion | ▲ +768.0% |
| 2018 | -0.01x | ₩-3.43 Billion | ₩330.51 Billion | ▼ -104.8% |
| 2017 | 0.22x | ₩5.92 Billion | ₩27.15 Billion | ▲ +360.9% |
| 2016 | 0.05x | ₩11.36 Billion | ₩239.91 Billion | ▲ +251.6% |
| 2015 | 0.01x | ₩2.74 Billion | ₩203.78 Billion | ▲ +151.0% |
| 2012 | -0.03x | ₩-3.94 Billion | ₩149.36 Billion | ▼ -117.1% |
| 2011 | 0.15x | ₩23.63 Billion | ₩152.74 Billion | — |